Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy

4 Jun 2025

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Monoclonal and Polyclonal Antibodies Research
Share to Viral Infectious Diseases and Gene Expression in Insects

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40472844
DOI: 10.1016/j.stem.2025.05.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacyPMID 40472844Read ↗

Chimeric Antigen Receptor (CAR) T Cells: A Detailed Review of Origins, Engineering, and Therapeutic ImpactSemantic proximity Read ↗

CAR‐T‐cell products in solid tumors: Progress, challenges, and strategiesSemantic proximity Read ↗

From molecular design to clinical translation: dual-targeted CAR-T strategies in cancer immunotherapySemantic proximity Read ↗

Engineering chimeric antigen receptor-T cells for cancer treatment.Semantic proximity Read ↗

T cells expressing a HER2-specific chimeric antigen receptor as treatment for breast cancerSemantic proximity Read ↗

Humanized CAR T cells targeting p95HER2Semantic proximity Read ↗

CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targetingSemantic proximity Read ↗

The Anticancer Potential of T Cell Receptor-Engineered T Cells.Semantic proximity Read ↗

Beyond Neoantigens: Antigens Derived from Tumor Drivers as Cancer Vaccine TargetsSemantic proximity Read ↗

Developing neoantigen-targeted T cell–based treatments for solid tumorsSemantic proximity Read ↗

CAR T Cells for Solid TumorsSemantic proximity Read ↗

Novel Approaches to Enhance the Specificity and Safety of Engineered T CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.